- Published at
- by seekingalpha.com
positive
positive
Biophytis unveils outlook strategies for 2025, to launch phase 3 of SARA clinical program
Biophytis SA (BPTSY) Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its commercialization.